CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

France at the Forefront of Biotech Innovation in Europe

France at the Forefront of Biotech...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Gene Therapy Clearly Communicated: The Importance of Patient-Centricity, Anan Omnichannel Approach, and Health Literacy

Gene Therapy Clearly Communicated:...

France at the Forefront of Biotech Innovation in Europe

France at the Forefront of Biotech...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Gene Therapy Clearly Communicated: The Importance of Patient-Centricity, Anan Omnichannel Approach, and Health Literacy

Gene Therapy Clearly Communicated:...

Is Deflation the Future of Biotech

Life Sciences Review | Wednesday, April 06, 2022
Tweet

The previous years were remarkable for biotech startups as the financing smashed all records. Now, as the pandemic weakens, inflation is on the rise, and the impact of the Russo-Ukraine conflict is intensifying, biotechs are in a bust phase.


FREMONT, CA: After the pandemic-driven investment boom in 2020, investment levels held steady through 2021 and brought in around the same amount, USD 36.3 billion. Asia is a region with growing biotech activity. Other companies that were active in funding and collaborating included those working on RNA therapeutics, adoptive immune cell therapy creators, and PROTAC (proteolysis-targeting chimaera) strategies. Investments involving machine learning also included financing. As pharma exhibited a stronger interest in partnerships, mergers decreased.


VC funding reached its high in the first quarter of last year and has since started to decrease gradually. According to market research companies, the sector has experienced a 10 per cent to 30 per cent decline. The pace of new stock offerings was the slowest in three years in the first quarter of 2022, indicating a more challenging funding climate. In 2020, the biotech uptrend began. The Nasdaq Biotechnology Index reached a high of 5392 points in 2021, and as of June 13, 2022, it was at 3368 points, a drop of 38 per cent. The biotech sector experiences fluctuations, much like all other sectors of the economy. Nevertheless, putting aside any short-term fluctuations, I believe that the sector's long-term trajectory has been positive and is continuing to do so, as healthcare spending has increased steadily and is now at


about 10% of GDP. The need for better healthcare and medications grows as the population ages, and this need is inherent to people's lives and unrelated to market conditions.


The sector has been modified at this moment. It will be difficult for early-stage businesses or first-time fundraisers to raise money. For a while, investors would steer clear of risky ventures in favour of more secure ones. Experts predict that investors will reinvest money from microcap startups into businesses that are already commercialising their products. They will consider companies in Phase 3 trials that also have sizable addressable markets after the markets have stabilised. Since the health technology industry is quickly expanding and has enormous long-term potential, VCs will continue to pay attention to it. More publicly traded biotech companies may be acquired by big pharma as a result of the price decline. The sector will recover, and finances won't dry up, according to experts.


The most successful startups have been those that have cutting-edge platform technologies, which serve as a foundation or infrastructure on which additional therapies can be built. Venture capitalists will continue to place their bets on such cutting-edge technologies. VCs will continue to pour money into fields like cell therapy 2.0, next-generation gene therapies, precision medicine, innovative delivery modalities, etc. It is not anticipated that the biotech industry would revert to its normal state before the pandemic. In a corporate climate that is rapidly changing, businesses will face numerous new issues that require adaptation. According to EY's Beyond Borders 2022 research, there are also enormous potential opportunities for biotech as it approaches the future, as 2021 showed.


Weekly Brief

loading

  • Top 10 Biotech Startup in Europe - 2021
  • Top 5 Biotech Startups In UK - 2021
  • Top 10 Biotech Startups in Europe - 2022
  • Top 5 Biotech Startups in UK - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/is-deflation-the-future-of-biotech-nwid-877.html